Advances in our understanding of cancer immunology and the mechanisms by which cancer immunotherapies exert their effects have translated into increasingly positive patient outcomes.
The recent successes of immunotherapeutics, particularly immune checkpoint inhibitors, have served to demonstrate the power and potential of immune-based treatment strategies. Now there is a need to build upon what we have learned in order to effectively treat more patients with cancer.
SITC Cancer Immunotherapy CONNECT is your hub for live and online educational opportunities. SITC CONNECT also provides access to all of the latest data in the field of tumor immunology and cancer immunotherapy. Connect to other researchers in the Cancer Immunotherapy CONNECT Open Forum and submit your manuscript to the Journal for ImmunoTherapy of Cancer (JITC) to drive progress in the field.
Registration is now open for the 2017 SITC Annual Meeting & Pre-Conference Programs, the premier destination for scientific exchange, education and networking in the cancer immunotherapy field. Click here to register for meeting, submit your latest research and more.
Be Part of the Breakthrough at the Charles River World Congress on Animal Models in Drug Discovery & Development. Boston | September 26-27, 2017 http://breakthroughs.criver.com/index.html ...
Use of mAb-based immunotherapies has resulted in major improvements in treatment of B-cell neoplasms, but patients can relapse, succumbing to the disease. An alternative approach that destroys ...
According to the cited pharma company document within, out of Hemel Hempstead, England, May 10, 2017, Dinutuximab beta, originally developed by the Vienna-based biotech company Apeiron Biologics ...
The European Commission has recently approved dinutuximab beta for high risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy in Europe for this ...
View More Researcher Resources
Launched in July of 2016, SITC presents the newest in a series of videos focusing on immunotherapy for NSCLC patients, the NSCLC Immunotherapy: Advancing HopeTM video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some of the available FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials.
For more than 30 years SITC (Society for Immunotherapy of Cancer) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com